#1 Clinical Trials Search in Europe

Donepezil

This article delves into the use of Donepezil, a widely studied drug for Alzheimer’s disease, in various clinical trials. We’ll examine how different dosages and formulations of Donepezil have been tested to treat severe Alzheimer’s disease, Dementia with Lewy Bodies (DLB), and other related conditions. The trials explore the drug’s efficacy, safety, and pharmacokinetics in diverse patient populations, providing valuable insights into its potential as a treatment option.

Table of Contents

What is Donepezil?

Donepezil is a medication primarily used to treat symptoms of Alzheimer’s disease and other forms of dementia. It is also known by its brand name Aricept and its research code E2020[1]. Donepezil belongs to a class of drugs called acetylcholinesterase inhibitors, which work by increasing certain chemical activities in the brain[2].

Conditions Treated by Donepezil

Donepezil is primarily used to treat:

  • Alzheimer’s Disease: It is used for mild, moderate, and severe stages of Alzheimer’s disease[2][3].
  • Dementia with Lewy Bodies (DLB): Studies have investigated its use in treating this form of dementia[1].

Interestingly, some research is exploring its potential use in treating:

  • Oxaliplatin-induced Peripheral Neuropathy: This is a type of nerve damage caused by certain chemotherapy drugs used in cancer treatment[4].

How Donepezil Works

Donepezil works by increasing the levels of a chemical called acetylcholine in the brain. Acetylcholine is important for memory, thinking, and reasoning. In Alzheimer’s disease and some other forms of dementia, the levels of this chemical are lower than normal. By increasing acetylcholine levels, donepezil may help improve symptoms related to memory, thinking, reasoning, and behavior[2].

Dosage Forms and Strengths

Donepezil comes in several dosage forms and strengths:

  • Immediate Release Tablets: Available in 3 mg, 5 mg, and 10 mg strengths[1].
  • Sustained Release Tablets: Available in 23 mg strength[5].

The dosage is typically started low and may be increased over time based on how well you tolerate the medication and how effective it is for you. Always follow your doctor’s instructions regarding dosage[3].

Effectiveness of Donepezil

The effectiveness of donepezil is typically measured using various tests and scales that assess cognitive function, daily living activities, and overall clinical impression. Some of these include:

  • Mini-Mental State Examination (MMSE): This test measures general cognitive functioning, including memory, attention, and language skills[1].
  • Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog): This scale assesses a range of cognitive abilities[2].
  • Clinician’s Interview-Based Impression of Change (CIBIC-plus): This measures overall clinical function based on both clinician and caregiver input[1].
  • Activities of Daily Living (ADL) scales: These measure a person’s ability to perform everyday tasks[2].

Studies have shown that donepezil can help improve or stabilize these measures in many patients, although individual responses may vary[2][1].

Potential Side Effects

Like all medications, donepezil can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Loss of appetite
  • Diarrhea
  • Muscle cramps
  • Fatigue
  • Difficulty sleeping

More serious side effects are less common but can occur. Always report any unusual symptoms to your healthcare provider[2].

Special Considerations

There are some special considerations to keep in mind with donepezil:

  • Kidney Function: If you have kidney problems, especially if you’re on dialysis, your doctor may need to adjust your dosage[6].
  • Genetic Factors: Your body’s ability to process donepezil can be affected by your genetic makeup, specifically related to an enzyme called CYP2D6. Your doctor may consider this when determining your dosage[5].
  • Combination with Other Medications: In some cases, donepezil may be used in combination with other Alzheimer’s medications. Always inform your doctor about all medications you’re taking[2].

Remember, while donepezil can help manage symptoms of Alzheimer’s disease and other forms of dementia, it does not cure these conditions. It’s important to have realistic expectations and to work closely with your healthcare team to monitor your progress and adjust treatment as needed.

Aspect Details
Drug Name Donepezil (also known as E2020, Aricept)
Primary Conditions Studied Severe Alzheimer’s disease, Dementia with Lewy Bodies (DLB)
Dosages Explored 3 mg, 5 mg, 10 mg, 23 mg
Formulations Immediate Release (IR), Sustained Release (SR)
Study Durations Ranging from 12 to 52 weeks
Key Outcome Measures MMSE, NPI, CIBIC-plus, ZBI
Special Populations Japanese subjects, patients on hemodialysis
Safety Assessments Adverse events, clinical laboratory tests, vital signs, ECG

FAQ

  • What is Donepezil and what is it used for? Donepezil, also known by the brand name Aricept, is a medication primarily used to treat Alzheimer's disease and Dementia with Lewy Bodies (DLB). It works by increasing certain brain chemicals that are involved in memory and thinking.
  • What dosages of Donepezil were studied in the clinical trials? The clinical trials explored various dosages of Donepezil, including 3 mg, 5 mg, 10 mg, and 23 mg. Some studies compared the efficacy and safety of different dosages, such as 23 mg versus 10 mg in patients with severe Alzheimer's disease.
  • How long did the clinical trials for Donepezil typically last? The duration of the clinical trials varied. Some studies lasted for 12 weeks, while others extended up to 52 weeks or longer. For example, one study evaluated the safety and efficacy of Donepezil over a 24-week period in patients with moderate to severe Alzheimer's disease.
  • What were some of the main outcomes measured in these trials? The trials measured various outcomes, including cognitive function using tests like the Mini-Mental State Examination (MMSE), psychiatric symptoms using the Neuropsychiatric Inventory (NPI), global clinical function using the Clinician's Interview-Based Impression of Change (CIBIC-plus), and caregiver burden using the Zarit Caregiver Burden Interview (ZBI).
  • Were there any studies on Donepezil for conditions other than Alzheimer's disease? Yes, some studies focused on the use of Donepezil in patients with Dementia with Lewy Bodies (DLB). Additionally, there was a pharmacokinetics study of Donepezil in subjects with end-stage renal disease who were receiving hemodialysis.

Ongoing Clinical Trials on Donepezil

  • Study on Donepezil Versus Non-drug Treatment for Patients with Alzheimer’s Disease

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

Glossary

  • Alzheimer's disease: A progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks.
  • Dementia with Lewy Bodies (DLB): A type of progressive dementia that leads to a decline in thinking, reasoning, and independent function due to abnormal microscopic deposits that damage brain cells.
  • Mini-Mental State Examination (MMSE): A widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills.
  • Neuropsychiatric Inventory (NPI): An assessment tool that measures various behavioral and psychological symptoms in patients with dementia.
  • Clinician's Interview-Based Impression of Change (CIBIC-plus): A global assessment tool used to evaluate a patient's overall clinical status in Alzheimer's disease trials.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Sustained Release (SR): A drug formulation designed to release the active ingredient slowly over time to maintain a consistent level in the bloodstream.
  • Immediate Release (IR): A drug formulation designed to release the active ingredient quickly after administration.
  • Last Observation Carried Forward (LOCF): A method used in clinical trials where missing values are replaced with the last observed value from that participant.
  • Cytochrome P450 2D6 (CYP2D6): An enzyme in the liver that metabolizes many drugs, including Donepezil.

References

  1. https://clinicaltrials.gov/study/NCT00543855
  2. https://clinicaltrials.gov/study/NCT00710684
  3. https://clinicaltrials.gov/study/NCT01539031
  4. https://clinicaltrials.gov/study/NCT05254639
  5. https://clinicaltrials.gov/study/NCT01276353
  6. https://clinicaltrials.gov/study/NCT01063556